Cellectis vs PureCycle Technologies
CLLS and PCT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and PCT compare
PureCycle Technologies grew revenue faster over the last twelve months (142% versus 75.8% for Cellectis).
Cellectis keeps more of each dollar of sales as profit, with a net margin of −92.7% compared with −1371% at PureCycle Technologies.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | PCT |
|---|---|---|
| Size and price | ||
| Market cap | – | $343M |
| Share price | $1.18 | $1.71 |
| Change, 1 year | −67.7% | −82.2% |
| Change, 5 years | −86.8% | −86.4% |
| Beta (5Y) | 2.07 | 1.82 |
| Employees | 229 | 174 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 25.0× |
| P/B | – | 18.5× |
| FCF yield | – | −61.0% |
| Fair value | – | $0.163 |
| Margin of safety | – | −943% |
| Growth | ||
| Revenue growth (TTM) | 75.8% | 142% (better) |
| Revenue growth, 5Y average | 7.4% | – |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −45.3% (better) | −1314% |
| Net margin | −92.7% (better) | −1371% |
| FCF margin | −57.2% (better) | −1528% |
| Return on equity | −97.8% (better) | −433% |
| Return on invested capital | −122% | – |
| Financial health | ||
| Interest coverage | −0.6× (better) | −2.9× |
| Current ratio | – | 1.60 |
| Altman Z-score | – | −1.61 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −46.7% |
| Shareholder yield | – | −46.7% |
| Ownership | ||
| Held by institutions | 9.4% | 90.6% |
| Held by insiders | 53.4% | 25.3% |
| Insider net buying, 12 months | – | $98.8K |
| Superinvestors holding | – | 1 |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- PCT stock overview
- PCT income statement
- PCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.